Drug
Interferon beta-1b clinical trials
Also written Betaferon®.
- studies test it
- 24
- open now
- 0
- in phase 3
- 6
- first study started
- 2002
How studies write it
Studies that test it under each name
Name
Brand
Other names
Combined with it in one product
Studies by the year they started
23 studies that test it; most in 2020 (6)
| Year | Studies |
|---|---|
| 2002 | 3 |
| 2003 | 5 |
| 2006 | 2 |
| 2007 | 2 |
| 2010 | 1 |
| 2012 | 2 |
| 2015 | 1 |
| 2017 | 1 |
| 2020 | 6 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 11
- Phase 3
- 6
- Phase 4
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 11
Bayer (10) · The University of Hong Kong (5) · Claudio Gobbi (2) · Tanabe Pharma Corporation (1) · University of Medicine and Dentistry of New Jersey (1) · Biogen (1) · Shahid Beheshti University of Medical Sciences (1) · Pfenex, Inc (1)
Often tested with
Tested in the same studies.
Ribavirin (3) · Interferon beta-1a (3) · Telaprevir (1) · Interferon beta (1) · Glatiramer (1) · Peginterferon beta-1a (1) · Atorvastatin (1) · Clofazimine (1)
Studies
Open first, then newest update. How each study uses Interferon beta-1b is read from its arms, and is right about nine times in ten.
Testing it · 24
- Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)CompletedPhase 3Tanabe Pharma CorporationNCT01753570Written as IFN beta(24 weeks)
- Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRICompletedPhase 4University of Medicine and Dentistry of New JerseyNCT00176592Written as Betaseron
- IFN-beta 1b and Remdesivir for COVID19Status unknownPhase 2The University of Hong KongNCT04647695Written as Interferon beta-1b
- Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current TherapyCompletedPhase 4BiogenNCT03177083Written as interferon beta-1b
- IFN Beta-1b and Ribavirin for Covid-19Status unknownPhase 2The University of Hong KongNCT04494399Written as Interferon beta-1b
- Double Therapy With IFN-beta 1b and HydroxychloroquineCompletedPhase 2The University of Hong KongNCT04350281Written as Interferon Beta-1B
- Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19Status unknownPhase 2The University of Hong KongNCT04465695Written as Interferon beta-1b
- An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical TrialCompletedPhase 2Shahid Beheshti University of Medical SciencesNCT04343768Written as Interferon Beta-1B
- Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV TreatmentCompletedPhase 2The University of Hong KongNCT04276688Written as Interferon Beta-1B
- Comparison Study of PF530 and Betaferon in Healthy SubjectsCompletedPhase 1Pfenex, IncNCT02474134Written as Interferon beta-1b (PF530, Betaferon)
- Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple SclerosisCompletedPhase 3BayerNCT00370071Written as Interferon beta-1b (Betaseron, BAY86-5046)
- BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New DoseCompletedPhase 3BayerNCT00459667Written as Interferon beta-1b (Betaseron, BAY86-5046)
- Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)WithdrawnPhase 3BayerNCT00313976Written as Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
- An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MSCompletedPhase 4BayerNCT00206648Written as Betaferon/Betaseron
- Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple SclerosisCompletedPhase 2BayerNCT00235989Written as Interferon beta 1b (Betaseron, BAY86-5046)
- Natalizumab De-escalation With Interferon Beta-1bCompletedPhase 4Claudio GobbiNCT01144052Written as interferon beta-1b
- Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple SclerosisTerminatedPhase 4Claudio GobbiNCT01701856Written as Interferon beta-1b
- BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up StudyCompletedPhase 3BayerNCT00185211Written as Interferon beta-1b (Betaseron, BAY86-5046)
- Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or RebifCompletedPhase 4BayerNCT00317941Written as Betaferon/Betaseron
- Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1bCompletedPhase 2Insel Gruppe AG, University Hospital BernNCT01111656Written as Interferon beta-1b group
See all 24 studies that test Interferon beta-1b →
Given in every arm · 1 — Interferon beta-1b is usual care beside what is tested
As the comparator · 5 — what is tested is compared with Interferon beta-1b
- Fingolimod Versus Interferon Beta 1b in Cognitive SymptomsCompletedPhase 4Novartis PharmaceuticalsNCT01333501Written as Interferon beta 1b
- Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy ChangeCompletedPhase 4Novartis PharmaceuticalsNCT01317004Written as Standard MS DMT
- A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple SclerosisCompletedPhase 4Novartis PharmaceuticalsNCT01216072Written as Standard MS DMTs
- RNF and Betaseron® Tolerability StudyCompletedPhase 3EMD SeronoNCT00428584Written as Interferon beta -1b
- Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMSTerminatedPhase 4Teva Branded Pharmaceutical Products R&D, Inc.NCT00202995Written as Betaseron
Codes
What other systems call Interferon beta-1b · ClinicalTrials.gg INT006518
- MeSH (NLM) D000068576Interferon beta-1bConfirmed ClinicalTrials.gov, Wikidata
- UNII (FDA) TTD90R31WZINTERFERON BETA-1BConfirmed FDA, Wikidata
- Wikidata Q1851162interferon beta-1bConfirmed FDA, Wikidata
- NCI Thesaurus C2221Interferon Beta-1BOne source FDA
- DrugBank DB00068One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068576 | Interferon beta-1b | Confirmed ClinicalTrials.gov, Wikidata |
| UNII (FDA) | TTD90R31WZ | INTERFERON BETA-1B | Confirmed FDA, Wikidata |
| Wikidata | Q1851162 | interferon beta-1b | Confirmed FDA, Wikidata |
| NCI Thesaurus | C2221 | Interferon Beta-1B | One source FDA |
| DrugBank | DB00068 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.